AU2023207765A1 - Bicyclic triazine derivatives for the treatment of cancer - Google Patents

Bicyclic triazine derivatives for the treatment of cancer Download PDF

Info

Publication number
AU2023207765A1
AU2023207765A1 AU2023207765A AU2023207765A AU2023207765A1 AU 2023207765 A1 AU2023207765 A1 AU 2023207765A1 AU 2023207765 A AU2023207765 A AU 2023207765A AU 2023207765 A AU2023207765 A AU 2023207765A AU 2023207765 A1 AU2023207765 A1 AU 2023207765A1
Authority
AU
Australia
Prior art keywords
trifluoromethyl
salt
cancer
methyl
triazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023207765A
Other languages
English (en)
Inventor
Philipp BUCHGRABER
Ulf Bömer
Sebastian DIETER
Hanno Glimm
Friederike HERBST-NOWROUZI
Sina KRETH
Philip Lienau
Gerhard Siemeister
Patrick STEIGEMANN
Kai Thede
Antje Margret Wengner
Frank Westermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Publication of AU2023207765A1 publication Critical patent/AU2023207765A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2023207765A 2022-01-11 2023-01-06 Bicyclic triazine derivatives for the treatment of cancer Pending AU2023207765A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22150829 2022-01-11
EP22150829.4 2022-01-11
PCT/EP2023/050208 WO2023135057A1 (en) 2022-01-11 2023-01-06 Bicyclic triazine derivatives for the treatment of cancer

Publications (1)

Publication Number Publication Date
AU2023207765A1 true AU2023207765A1 (en) 2024-07-04

Family

ID=79927598

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023207765A Pending AU2023207765A1 (en) 2022-01-11 2023-01-06 Bicyclic triazine derivatives for the treatment of cancer

Country Status (9)

Country Link
US (1) US20250066370A1 (https=)
EP (1) EP4463458A1 (https=)
JP (1) JP2025502240A (https=)
KR (1) KR20240134962A (https=)
CN (1) CN118541372A (https=)
AU (1) AU2023207765A1 (https=)
CA (1) CA3246440A1 (https=)
IL (1) IL313835A (https=)
WO (1) WO2023135057A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021176045A1 (en) * 2020-03-06 2021-09-10 Bayer Aktiengesellschaft Imidazotriazines acting on cancer via inhibition of cdk12

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011529072A (ja) 2008-07-24 2011-12-01 セラヴァンス， インコーポレーテッド 二重作用血圧降下薬
US8791162B2 (en) 2011-02-14 2014-07-29 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
MX2019012431A (es) 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
TW202146416A (zh) 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
WO2021176045A1 (en) 2020-03-06 2021-09-10 Bayer Aktiengesellschaft Imidazotriazines acting on cancer via inhibition of cdk12
WO2021176049A1 (en) 2020-03-06 2021-09-10 Bayer Aktiengesellschaft Pyrazolopyrazines acting on cancers via inhibition of cdk12

Also Published As

Publication number Publication date
KR20240134962A (ko) 2024-09-10
WO2023135057A1 (en) 2023-07-20
EP4463458A1 (en) 2024-11-20
CN118541372A (zh) 2024-08-23
CA3246440A1 (en) 2023-07-20
JP2025502240A (ja) 2025-01-24
US20250066370A1 (en) 2025-02-27
IL313835A (en) 2024-08-01

Similar Documents

Publication Publication Date Title
EP3532474B1 (en) 4,5-annulated 1,2,4-triazolones
EP3661517B1 (en) Dihydrooxadiazinones
WO2018024602A1 (en) 2,7-diazaspiro[4.4]nonanes
EP3710456B1 (en) Macrocyclic indole derivatives
AU2021231312A1 (en) Imidazotriazines acting on cancer via inhibition of CDK12
EP3390387B1 (en) Heteroarylbenzimidazole compounds
EP3710449B1 (en) Macrocyclic fluorine substituted indole derivatives as mcl-1 inhibitors, for use in the treatment of cancer
AU2020399184A1 (en) Pyrazolotriazines
WO2017202817A9 (en) [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl] (1h-1,2,3-triazol-4-yl)methanones
US20250170136A1 (en) 1,2,4-triazin-3(2h)-one compounds for the treatment of hyperproliferative diseases
EP4114837A1 (en) Pyrazolopyrazines acting on cancers via inhibition of cdk12
AU2023207765A1 (en) Bicyclic triazine derivatives for the treatment of cancer
WO2017207534A1 (en) Substituted heteroarylbenzimidazole compounds
WO2018114670A1 (en) [4-(phenylsulfonyl)piperazin-1-yl](1h-1,2,3-triazol-4-yl)methanones
HK40085534A (en) Imidazotriazines acting on cancer via inhibition of cdk12
WO2018114677A2 (en) [(phenylsulfonyl)octahydro-epiminoisoindol-yl](1h-1,2,3-triazol-5-yl)methanones
EP3555067A1 (en) [4-(phenylsulfonyl)piperazin-1-yl](1h-1,2,3-triazol-4-yl)methanones